Title
Understanding Adult Participant and Parent Empowerment Prior to Evaluation in the Undiagnosed Diseases Network.

Permalink
https://escholarship.org/uc/item/22q6q61h

Journal
Journal of genetic counseling, 27(5)

ISSN
1059-7700

Authors
Palmer, Christina GS
McConkie-Rosell, Allyn
Holm, Ingrid A
et al.

Publication Date
2018-09-01

DOI
10.1007/s10897-018-0228-6

Peer reviewed
Understanding Adult Participant and Parent Empowerment Prior to Evaluation in the Undiagnosed Diseases Network

Christina G. S. Palmer 1,2,3 • Allyn McConkie-Rosell 4 • Ingrid A. Holm 5,6,7 • Kimberly LeBlanc 8 • Janet S. Sinsheimer 2,3,9,10 • Lauren C. Briere 11 • Naghmeh Dorrani 12 • Matthew R. Herzog 2 • Sharyn Lincoln 5 • Kelly Schoch 4 • Rebecca C. Spillmann 4 • Elly Brokamp 13 • Undiagnosed Diseases Network

Received: 17 August 2017 / Accepted: 29 January 2018 © The Author(s) 2018. This article is an open access publication

Abstract

The burden of living with an undiagnosed condition is high and includes physical and emotional suffering, frustrations, and uncertainty. For patients and families experiencing these stressors, higher levels of empowerment may be associated with better outcomes. Thus, it is important to understand the experiences of patients with undiagnosed conditions and their families affected by undiagnosed conditions in order to identify strategies for fostering empowerment. In this study, we used the Genetic Counseling Outcome Scale (GCOS-24) to assess levels of empowerment and support group participation in 35 adult participants and 67 parents of child participants in the Undiagnosed Diseases Network (UDN) prior to their UDN in-person evaluation. Our results revealed significantly lower empowerment scores on the GCOS-24 in adult participants compared to parents of child participants [t(100) = −3.01, p = 0.003, average difference = −11.12, 95% CI (−3.78, −18.46)] and no significant association between support group participation and empowerment scores. The majority of participants (84.3%, 86/102) are not currently participating in any support groups, and participation rates were not significantly different for adult participants and parents of child participants (11.4 vs. 19.7%, respectively, FE p = 0.40). Open-ended responses provided additional insight into support group participation, the challenges of living with undiagnosed conditions, and positive coping strategies. Future research will evaluate the extent to which empowerment scores change as participation in the UDN unfolds.

Keywords Empowerment • Support groups • Undiagnosed disease • Undiagnosed condition • Genetic counseling

List of member names is provided at the end of this article.

© The Author(s) 2018. This article is an open access publication

Published online: 01 March 2018

The burden of living with an undiagnosed condition is high and includes physical and emotional suffering, frustrations, and uncertainty. For patients and families experiencing these stressors, higher levels of empowerment may be associated with better outcomes. Thus, it is important to understand the experiences of patients with undiagnosed conditions and their families affected by undiagnosed conditions in order to identify strategies for fostering empowerment. In this study, we used the Genetic Counseling Outcome Scale (GCOS-24) to assess levels of empowerment and support group participation in 35 adult participants and 67 parents of child participants in the Undiagnosed Diseases Network (UDN) prior to their UDN in-person evaluation. Our results revealed significantly lower empowerment scores on the GCOS-24 in adult participants compared to parents of child participants [t(100) = −3.01, p = 0.003, average difference = −11.12, 95% CI (−3.78, −18.46)] and no significant association between support group participation and empowerment scores. The majority of participants (84.3%, 86/102) are not currently participating in any support groups, and participation rates were not significantly different for adult participants and parents of child participants (11.4 vs. 19.7%, respectively, FE p = 0.40). Open-ended responses provided additional insight into support group participation, the challenges of living with undiagnosed conditions, and positive coping strategies. Future research will evaluate the extent to which empowerment scores change as participation in the UDN unfolds.

Keywords Empowerment • Support groups • Undiagnosed disease • Undiagnosed condition • Genetic counseling

List of member names is provided at the end of this article.
Introduction

Rare diseases, when considered as a group, affect 25–30 million individuals in the US population (National Institutes of Health 2017), and more than half of those with rare diseases are children (EURORDIS 2018). Although roughly 80% of undiagnosed conditions are believed to be genetic in origin (Chong et al. 2015), for many patients and families, an underlying genetic cause is not found. As a result, too often, patients and families find themselves continuing on the diagnostic odyssey searching for answers (Molster et al. 2016; Zurynski et al. 2017).

The Undiagnosed Diseases Network (UDN; https://undiagnosed.hms.harvard.edu/) is a clinical research endeavor with the goal of ending the diagnostic odyssey for patients and families by identifying the underlying etiology of undiagnosed conditions. Participation in the UDN involves extensive phenotyping during a 1–5-day in-person evaluation at a participating UDN clinical site by a multidisciplinary team including clinical geneticists and genetic counselors during which biospecimen samples are taken and clinical tests are conducted; next-generation sequencing for most participants; and follow-up research, such as functional gene variant analyses (Gahl et al. 2015; Ramoni et al. 2017). The UDN is composed of seven clinical sites (Baylor College of Medicine, Duke University Health System with Columbia University Medical Center [Duke], Harvard Affiliated Hospitals [Brigham and Women’s Hospital, Massachusetts General Hospital, and Boston Children’s Hospital] [Harvard], Stanford Medical Center, University of California Los Angeles [UCLA], Vanderbilt University Medical Center [Vanderbilt], National Institutes of Health Undiagnosed Disease Program), two DNA sequencing cores (Baylor College of Medicine for whole exome sequencing, HudsonAlpha with Illumina for whole genome sequencing), a metabolomics core (Oregon Health and Science University and Pacific Northwest National Laboratory), a model organisms screening center (Baylor College of Medicine and University of Oregon), a biorepository (Vanderbilt University Medical Center), and a coordinating center (Harvard Medical School). In the UDN context, participants receive genetic counseling during the informed consent process to discuss the genetic testing options and possible results and during the in-person evaluation to discuss the available findings. All participants have the opportunity to ask questions and discuss clinical genetic testing that was done prior to their admission to the UDN. Some participants receive genetic counseling in the context of a diagnosis during the initial in-person evaluation, while for others, a diagnosis and updated genetic counseling may not occur until months or years after the in-person evaluation. Additional genetic counseling may occur after the end of the in-person evaluation based on the need of the participant and their families. The UDN provides an ideal venue to study the experience of living with an undiagnosed condition.

A recent study of applicants to the UDN provides some initial insight into the experiences of these patients and families (Spillmann et al. 2017). As part of the application process at the Duke clinical site, adult patients and parents of patients incapable of providing consent, including parents of children, were asked to include a written narrative describing their or their child’s medical history from their perspective. Analysis of 20 adult patient and 20 parent narratives found that consistent with other studies (Lewis et al. 2010; Madeo et al. 2012; Yanes et al. 2017; Zurynski et al. 2017), that the burden of living with an undiagnosed condition is high and includes physical and emotional suffering, frustrations, and much uncertainty.

Despite the commonalities between the narratives of adult patients and those of parents, there were also notable differences. This is a significant finding because, while there is some literature on parents’ experiences with undiagnosed conditions, there is a dearth of information on the experiences of adults with undiagnosed conditions. Spillmann and colleagues found that while both adult patients and parents were hopeful that the UDN experience would lead to a diagnosis, their thoughts about the impact of having a diagnosis differed. For the majority of adult patients, having a diagnosis meant being able to explore treatment options so that they could resume the lives they had led prior to onset of illness. For parents, however, having a diagnosis meant reducing uncertainty about what the future may hold and gaining information to improve management and quality of life for their children, consistent with previous research (Lewis et al. 2010; Zurynski et al. 2017). Both groups also noted frustration with medical providers, but for different reasons. For adult patients, this frustration often stemmed from the need to validate symptoms in light of nondiagnostic testing, while for parents it was caused by a concern that evidence crucial to making a diagnosis was being overlooked. Both parents and adult patients felt that they had exhausted all other diagnostic options. Similar to Lewis et al. (2010), parents also described the complexity of care required by their child and their role as an advocate to improve their child’s quality of life, even in the absence of a cure. While some parents expressed helplessness and distress at being unable to improve their child’s outcome, the majority emphasized their child’s positive attributes. Focusing “on the positive” has been observed in other studies of parents with a child with an undiagnosed condition as well (Lewis et al. 2010).

These narratives revealed how valuable and, in some cases, emotional it was for parents and adult patients to “tell their story,” suggesting that patients and families with undiagnosed conditions lack a support system or network of “similar others.” The findings that adult patients and parents experience undiagnosed conditions differently demonstrates the
Patient empowerment is a key strategy to provide patients and parents with support. Empowerment is a process involving acquisition of knowledge and skills, utilization of resources, and involvement with similar others with the goal of enhancing outcomes and developing positive coping strategies (McConkie-Rosell and Sullivan 1999). Importantly, these are components in which medical providers can have a direct hand. Empirical data suggest that empowerment can improve cost-effective use of health services (Wallerstein 2006) and may lead to more informed decisions and positive outcomes for patients and families (McAllister et al. 2008).

Patient empowerment, as a process and as an outcome, has been studied in patients with chronic conditions (Bolen et al. 2014; Chen et al. 2013; Schmidt et al. 2015) and, more recently, in patients seeking genetic services (Diness et al. 2017; Inglis et al. 2015; McAllister 2016; McAllister et al. 2011). Since the majority of genetic conditions do not yet have treatment, studying patient empowerment in this cohort can provide insight into how the delivery of care itself influences empowerment.

There is some evidence that obtaining clinical genetics services increases patients’ sense of empowerment. Patient empowerment 2–4 weeks after an evaluation in a genetics clinic in the UK was higher than prior to the evaluation in a sample of patients with a variety of conditions, including those seeking a diagnosis (McAllister et al. 2011). In this study, levels of empowerment were not associated with type of condition, age, gender, ethnicity, or reason for referral. However, support group participation was associated with greater empowerment, highlighting the importance of providing this resource.

In another study, increased empowerment 1-month post-psychiatric genetic counseling, a setting in which providers do not typically provide etiologic diagnoses, was also observed (Inglis et al. 2015). The results of these studies that include individuals with conditions that remained undiagnosed support the fact that there are components to the process of delivering care, distinct from identifying an underlying etiology, that are important for enhancing patient empowerment. Moreover, Inglis et al. (2015) found that individuals with and without a personal history of mental illness experienced increased empowerment, supporting the fact that there are benefits of the counseling process for individuals with and without disease.

These studies suggest that factors that contribute positively, or negatively, to patient and parent empowerment can be identified. Given the differences observed between adult patients and parents by Spillmann et al. (2017), evaluating these two groups individually may provide insights to guide interventions specific to each group. The UDN offers a unique opportunity to follow participants and parents going through a comprehensive clinical and research evaluation and to assess how, and to what extent, participants and parents become empowered by their experiences in the Network. In order to understand how the in-person evaluation may impact empowerment, it is critical to examine and understand the experience of this population at the beginning of their participation and to gain insight into baseline levels of empowerment, which can then be compared to empowerment levels after the evaluation. Thus, the purpose of our study was twofold: (1) to provide a description of UDN participant and parent levels of empowerment and support group participation prior to the UDN in-person evaluation and (2) to identify covariates of baseline empowerment in our UDN sample.

**Methods**

**Study Design**

The larger UDN empowerment study is a prospective longitudinal study of adult participant and parent empowerment with three assessment time points. The first assessment (T1) occurs after enrollment into the UDN and prior to the in-person evaluation; the second (T2) and third (T3) assessments occur 1 month and 1 year, respectively, after completion of the in-person evaluation. For this study of empowerment at baseline, we focus on T1 surveys completed between August 2016 and March 2017. The central Institutional Review Board (IRB) for the UDN, which is at the National Human Genome Research Institute (NHGRI), approved the study protocol.

**Participants**

The study took place at four UDN clinical sites: Duke, Harvard, UCLA, and Vanderbilt. Adult UDN participants capable of providing consent and parents of UDN participants incapable of providing consent (i.e., minors, adults without capacity to consent) were invited to participate in the study. Non-English-using participants and biologically unrelated caregivers were excluded.

**Measures**

The Genetic Counseling Outcome Scale (GCOS-24) was used to measure empowerment (McAllister et al. 2011). This patient-reported outcomes measure designed for clinical genetics services defines empowerment as the belief that one: (1) can make important life decisions in an informed way (decisional control); (2) has sufficient information about the condition, including risks to oneself and one’s relatives, and any treatment, prevention, and support available (cognitive control); (3) can make effective use of the health and social care
systems for the benefit of the whole family (behavioral control); (4) can manage one’s feelings about having a genetic condition in the family (emotional regulation); and (5) can look to the future having hope for a fulfilling family life, for oneself, one’s family, and/or one’s future descendants (hope). The GCOS-24 has been validated in a clinical genetics population (n = 395) that included undiagnosed patients; has excellent internal consistency (Cronbach’s alpha = 0.87), test-retest reliability (r = 0.86), and convergent and divergent validities; and shows sensitivity to change over time with a medium-to-large effect size (McAllister et al. 2011). This measure has also been used to assess empowerment as an outcome of psychiatric genetic counseling (Inglis et al. 2015). Each of the 24 items in the measure is rated on a 7-point Likert scale ranging from 1 (strongly disagree) to 7 (strongly agree) with possible total scores ranging from 24 to 168. Higher scores indicate higher levels of empowerment.

We conducted a pilot study of this empowerment measure with 21 UDN participants, which demonstrated similar performance metrics as those described by McAllister et al. (2011). Based on pilot study feedback, the instructions were modified slightly to include the following: “Clinical genetics service refers to the UDN clinical visit. Condition refers to the reason you or your child is being evaluated in the UDN.”

For the final survey, an additional question was asked in multiple choice format to ascertain participation in support groups, and those who reported participation were asked to describe the group(s) in a free-response format. Participants were also encouraged to provide comments at the end of the survey. Demographic and family history information, including primary symptom category, was obtained from the data collected for the broader UDN protocol.

Procedures

After enrollment and prior to the start of the UDN in-person evaluation, participants received an invitation email that contained a link to the T1 survey. When necessary, a paper and pencil version of the survey was made available in-person or by mail. During the consenting process for enrollment in the UDN, participants were informed about completing surveys; however, survey completion was voluntary and did not affect UDN participation.

Data Analysis

As described by McAllister et al. (2011), relevant GCOS-24 items were reverse coded, and an overall empowerment score was calculated as the sum of the 24-item scores. Per the recommended procedure, missing data were filled in using simple imputation for surveys with greater than 75% completion (Inglis et al. 2015; McAllister et al. 2011) in order to compute a total empowerment score.

Pearson’s correlation and Fisher’s exact test were performed to evaluate association between quantitative or categorical variables, respectively. T tests were performed to compare group differences on quantitative variables. To explore participant group differences on individual GCOS-24 items, responses to each item were collapsed into three categories [disagree (containing strongly disagree, disagree, and slightly disagree responses), neutral, and agree (containing strongly agree, agree, slightly agree responses)] and assessed using Fisher’s exact test; imputed data were excluded from these analyses. Statistical significance was set at p < 0.05. No correction for multiple testing was used.

Free responses of the comments section were systematically analyzed using conventional content analysis with Atlas Ti (version 7; http://atlasti.com/). Content analysis allows for coding and categorization of the emerging themes without the use of theory (Hsieh and Shannon 2005; Satu et al. 2014). Initial coding was done by AMR. Once coding was complete, data were organized into the emerging themes and then reviewed by AMR and CP. Respondents were specifically asked if they belonged to support group(s) and, if so, to name it. These responses were then classified based on the type of support group.

Results

Demographic Characteristics

A total of 183 T1 surveys were distributed and 71% (130/183) were completed by participants prior to their UDN in-person evaluation from August 15th, 2016, to March 31st, 2017 (Duke: n = 34, Harvard: n = 31, UCLA: n = 31, Vanderbilt: n = 34). Among the remaining 53 participants who did not complete the survey, 12 were considered nonresponders because their in-person evaluations occurred before the analysis cutoff date, and 41 were considered to have pending surveys because their in-person evaluation was scheduled to occur after the analysis cutoff date.

Of the 130 surveys received, 27% (35/130) were completed by adult participants, 28% (36/130) were completed by mothers of participants, and 4% (5/130) were completed by fathers of participants. The remaining 54 surveys were completed by 27 mother-father dyads. Less than 1% of the GCOS-24 items were missing responses (25 out of 3120 item responses) with no single respondent missing more than 5 items. For those surveys with item responses missing more than 5 items, data were imputed. Internal consistency of the GCOS-24 items was assessed on 116 surveys with complete data, and the resulting Cronbach’s alpha of 0.84 was consistent with
other studies using this measure (Inglis et al. 2015; McAllister et al. 2011).

In the 27 cases in which both parents filled out surveys, we found that the mother-father dyad empowerment scores were significantly correlated \((r = 0.58, 95\% \text{ CI } 0.25, 0.78)\). Thus, in order to satisfy the assumption of independent observations underlying the \(t\) test, one parent was randomly excluded from each of the dyads for subsequent analysis. There also was one instance where both an adult female participant and her husband completed a survey. In this case, we retained only the adult participant’s survey for analysis to eliminate potential response dependency. This resulted in a final sample size of 102 respondents with a fairly even distribution across the four clinical sites (Duke: \(n = 25\), Harvard: \(n = 26\), UCLA: \(n = 23\), Vanderbilt: \(n = 28\)).

Demographic characteristics of participants with an undiagnosed condition (adults and those incapable of providing consent) are presented in Table 1. The 35 adult participants are composed of 22 females and 13 males (mean age = 43.2 years, SD 15.8), and the 67 participants incapable of providing consent are composed of 32 females and 35 males (mean age = 9.3 years, SD 7.5). The primary race of the UDN participant was reported as Caucasian (88.2%, 90/102), with 96.1% (98/102) of UDN adult and child participants identifying as non-Hispanic. The predominant symptom category of the UDN participants was neurology (48.0%, 49/102).

Demographic characteristics of the parents of children with an undiagnosed condition are also presented in Table 1. For parent respondents, the mean age was 41.2 years (SD 8.5), and 4.5% (3/67) reported being affected. Five parents of adult participants incapable of consent completed the surveys and these responses are included in the parent sample.

For adult participant respondents, 42% (15/30) reported having children, 42% (15/30) reported not having children, and no information was available for the remaining five adult participants. Adult participants with children were significantly older (mean age = 47.5 years, SD 14.5) than those without children (mean age = 36.6 years, SD 12.4) \([t(28) = -2.23, p = 0.03]\). Adult participants were less likely to fall into the “neurology” symptom category than children/participants incapable of providing consent \((FE \ p = 0.02)\).

**Empowerment**

The average score on the GCOS-24 measure was 112.66 (SD 18.42, min 69, max 156). Scores were significantly lower for adult participants \((mean = 105.4, SD 16.94)\) than for parents \((mean = 116.5, SD 18.1)\) \([t(100) = -3.01, \ p = 0.003, \text{ average difference} = -11.12, 95\% \text{ CI } (-3.78, -18.46)\]. To further evaluate this apparent distinction between adult participants and parents, we compared the baseline GCOS-24 scores from our respondents to scores obtained from adults with a psychiatric illness of unknown etiology prior to genetic counseling \((n = 45, \text{ mean} = 109.20, \text{ SD } 14.7)\) (Inglis et al. 2015). There was no significant difference between the UDN adult participants and adults with a psychiatric illness \([t(67) = 1.08, \ p = 0.28, \text{ average difference} = 3.89, 95\% \text{ CI } (-3.31, 11.09)]\); however, the adults with a psychiatric illness had significantly lower scores than our UDN parents \([t(105) = -2.32, \ p = 0.02, \text{ average difference} = -7.21, 95\% \text{ CI } (-13.38, -1.04)\].

Because five items ask specifically about (future) children, we assessed if the score difference was an artifact produced by responses of adult participants without children. To evaluate this, responses from these five items were excluded and new scores were calculated for all respondents. Scores remained significantly lower for adult participants \((mean = 81.6, SD 14.65)\) than for parents \((mean = 90.87, SD 15.4)\) \([t(100) = -2.93, \ p = 0.004, \text{ average difference} = -9.27, 95\% \text{ CI } (-3.0, -15.54)\].

Empowerment scores were not associated with respondent gender \([t(98) = 0.93, \ p = 0.35]\), support group participation \([t(94) = -0.11, \ p = 0.91]\), age \([r = -0.04, \ p = 0.72]\), or the primary symptom category of the UDN participant \([t(100) = 0.71, \ p = 0.48]\). In addition, in a separate analysis of parents, their scores were not associated with parental status (mother/father) \([t(66) = 0.15, \ p = 0.88]\), their child’s age \([r = -0.07, \ p = 0.58]\), child’s gender \([t(65) = -1.37, \ p = 0.18]\), or child’s race (Caucasian/other) \([t(65) = 0.85, \ p = 0.40]\).

The response distribution for each item on the GCOS-24 was compared between adult participants and parents to gain further insight into group differences. Table 2 lists the GCOS-24 items in descending order of percent agreement for the adult participants and identifies the items for which there are significant differences in response distribution between the two groups. Examination of specific items on the empowerment measure revealed that nearly all participants and parents understood why they were referred to the UDN for evaluation. In addition, the majority of respondents felt that they could explain what the condition meant to their family and others, could cope with having the condition in the family, felt positive about the future, could make plans and decisions, and understand the impact of the condition on (future) children. However, more than half of respondents also felt that the condition was upsetting and that they experience uncertainty about other family members having the condition.

Group differences were also observed. Compared to adult participants, parents were more likely to report agreement on “I am hopeful that my children can look forward to a rewarding family life” \((p = 0.0001)\), “I know how to get the non-medical help I/my family needs (e.g. educational, financial, social support)” \((p = 0.047)\), and “I can see that good things have come from having this condition in my family” \((p = 0.006)\). Compared to adult participants, parents were more likely to disagree with “I don’t know what could be gained from each of the options available to me” \((p = 0.026)\). Parents were less likely to report a neutral response and more likely to
disagree with the statement “I feel guilty because I (might have) passed this condition on to my children” \( (p = 0.003) \).

### Support Group Participation

The majority of respondents indicated that they do not participate in any support groups (84.3%, 86/102). In addition, the rates of participation were not significantly different for adult participants and parents of child participants (11.4 vs. 19.7%, respectively, \( FE p = 0.40 \)) (Table 1).

A total of 33 support groups were described by the 16 respondents (4 adult participants, 12 parents) who reported support group participation. Coding of these groups suggests six categories of support groups: general, special needs, symptom focus, specific disease, rare disease, and undiagnosed disease (Table 3). The categories with the largest number of support groups identified were special needs (24%, 8/33) and

| Table 1 Demographic characteristics | Total \((n = 102)\) | Adult participants \((n = 35)\) | Participants incapable of providing consent \((n = 67)\) |
|-------------------------------------|-------------------|-----------------------------|-----------------------------------|
| Sex                                 |                   |                             |                                   |
| Females, \(n \%(%)\)                | 54 (52.9)         | 22 (62.9)                   | 32 (47.8)                         |
| Males, \(n \%(%)\)                  | 49 (47.1)         | 13 (37.1)                   | 35 (52.9)                         |
| Age\(^a\)                           | \(20.9 \pm 19.5\) | \(43.2 \pm 15.8\)          | \(9.3 \pm 7.5\)                   |
| Race                                |                   |                             |                                   |
| Caucasian, \(n \%(%)\)              | 90 (88.2)         | 32 (94.1)                   | 58 (86.6)                         |
| Black or African-American, \(n \%(%)\) | 3 (2.97)       | 0 (0)                       | 3 (4.5)                           |
| Asian, \(n \%(%)\)                  | 3 (2.97)          | 0 (0)                       | 3 (4.5)                           |
| Other, \(n \%(%)\)                  | 5 (4.95)          | 2 (5.9)                     | 3 (4.5)                           |
| Ethnicity                           |                   |                             |                                   |
| Hispanic, \(n \%(%)\)               | 4 (3.9)           | 0 (0)                       | 4 (6.5)                           |
| Non-Hispanic, \(n \%(%)\)           | 98 (96.1)         | 35 (100)                    | 64 (94.1)                         |
| Primary symptom category            |                   |                             |                                   |
| Neurology, \(n \%(%)\)              | 49 (48.0)         | 11 (31.4)                   | 38 (56.7)                         |
| Other, \(n \%(%)\)                  | 11 (10.8)         | 4 (11.4)                    | 7 (10.5)                          |
| Rheumatology, \(n \%(%)\)           | 7 (6.9)           | 4 (11.4)                    | 3 (4.5)                           |
| Allergies, \(n \%(%)\)              | 6 (6.0)           | 4 (11.4)                    | 2 (3.0)                           |
| Cardiology, \(n \%(%)\)             | 6 (6.0)           | 4 (11.4)                    | 2 (3.0)                           |
| Musculoskeletal, \(n \%(%)\)        | 6 (6.0)           | 2 (5.7)                     | 4 (6.0)                           |
| Gastroenterology, \(n \%(%)\)       | 5 (4.9)           | 0 (0)                       | 5 (7.5)                           |
| N/A, \(n \%(%)\)                    | 4 (3.9)           | 3 (8.6)                     | 1 (1.5)                           |
| Endocrinology, \(n \%(%)\)          | 3 (2.9)           | 0 (0)                       | 2 (3.0)                           |
| Ophthalmology, \(n \%(%)\)          | 1 (0.98)          | 1 (2.9)                     | 0 (0)                             |
| Pulmonology, \(n \%(%)\)            | 1 (0.98)          | 1 (2.9)                     | 0 (0)                             |
| Hematology, \(n \%(%)\)             | 1 (0.98)          | 0 (0)                       | 1 (1.5)                           |
| Psychiatry, \(n \%(%)\)             | 1 (0.98)          | 0 (0)                       | 1 (1.5)                           |
| Nephrology, \(n \%(%)\)             | 1 (0.98)          | 0 (0)                       | 1 (1.5)                           |
| Support group participation, \(n \%(%)\) | N/A              | 4 (11.4)                    | N/A                               |
| Parental sex                        |                   |                             |                                   |
| Females, \(n \%(%)\)                | N/A               | N/A                         | 53 (77.1)                         |
| Males, \(n \%(%)\)                  | N/A               | N/A                         | 14 (20.8)                         |
| Parental age\(^a\)                  | N/A               | N/A                         | 41.2 \( \pm 8.5\)                 |
| Parental affected status, \(n \%(%)\)| N/A               | N/A                         | 3 (4.5)                           |
| Parental support group participation, \(n \%(%)\) | N/A             | N/A                         | 12 (19.7)                         |

\(^a\) The mean age ± standard deviation (in years) is indicated
Table 2  GCOS-24 item distributions for UDN adult participants and parents of UDN participants unable to provide consent

| Item                                                                 | Adult participants (n = 35) | Parents (n = 67) | p* |
|---------------------------------------------------------------------|----------------------------|-----------------|----|
|                                                                    | Agree % (n)                | Neutral % (n)   | Disagree % (n) | Agree % (n) | Neutral % (n) | Disagree % (n) |    |
| [1b] I am clear in my own mind why I am attending the clinical genetics service. | 97.1 (34)                  | 0               | 2.9 (1)        | 98.5 (66)   | 0               | 1.5 (1)        | 1.0 |
| [14] I understand the reasons why my doctor referred me to the clinical genetics service. | 97.1 (34)                  | 2.9 (1)         | 0              | 97.0 (65)   | 1.5 (1)         | 1.5 (1)        | 1.0 |
| [23] I understand what concerns brought me to the clinical genetics service. | 91.4 (32)                  | 5.7 (2)         | 2.9 (1)        | 95.5 (64)   | 1.5 (1)         | 3.0 (2)        | 0.55|
| [2] I can explain what the condition means to people in my family who may need to know. | 85.7 (30)                  | 0               | 14.3 (5)       | 82.1 (55)   | 6.0 (4)         | 11.9 (8)       | 0.44|
| [9] I am able to cope with having this condition in my family.      | 70.6 (24)                  | 11.8 (4)        | 17.7 (6)       | 78.8 (52)   | 7.6 (5)         | 13.6 (9)       | 0.58|
| [18] I don’t know who else in my family might be at risk for this condition (reverse coded item). | 69.7 (23)                  | 18.2 (6)        | 12.1 (4)       | 60.6 (40)   | 15.2 (10)       | 24.2 (16)      | 0.38|
| [16] I can explain what the condition means to people outside my family who may need to know (e.g., teachers, social workers). | 68.6 (24)                  | 11.4 (4)        | 20.0 (7)       | 77.6 (52)   | 9.0 (6)         | 13.4 (9)       | 0.57|
| [11c] Having this condition in my family makes me feel anxious.     | 62.9 (22)                  | 14.3 (5)        | 22.9 (8)       | 61.2 (41)   | 14.9 (10)       | 23.9 (16)      | 1.0 |
| [8] I feel positive about the future                              | 60.0 (21)                  | 20.0 (7)        | 20.0 (7)       | 61.2 (41)   | 17.9 (12)       | 20.9 (14)      | 0.96|
| [17c] I don’t know what I can do to change how this condition affects me/my children. | 60.0 (21)                  | 25.7 (9)        | 14.3 (5)       | 46.3 (31)   | 22.4 (15)       | 31.3 (21)      | 0.17|
| [20] I am able to make plans for the future.                      | 58.8 (20)                  | 11.8 (4)        | 29.4 (10)      | 70.2 (47)   | 9.0 (6)         | 20.9 (14)      | 0.46|
| [3] I understand the impact of the condition on my child(ren)/any child I may have. | 57.1 (20)                  | 28.6 (10)       | 14.3 (5)       | 71.6 (48)   | 13.4 (9)        | 14.9 (10)      | 0.19|
| [24] I can make decisions about my condition that may change my child(ren)’s future/the future of any child(ren) I may have. | 57.1 (20)                  | 31.4 (11)       | 11.4 (4)       | 70.8 (46)   | 18.5 (12)       | 10.8 (7)       | 0.29|
| [12] I don’t know if this condition could affect my other relatives (brothers, sisters, aunts, uncles, cousins). | 55.9 (19)                  | 8.8 (3)         | 35.3 (12)      | 48.5 (32)   | 13.6 (9)        | 37.9 (25)      | 0.69|
| [19] I am hopeful that my children can look forward to a rewarding family life. | 54.3 (19)                  | 45.7 (16)       | 0              | 83.6 (56)   | 10.5 (7)        | 6.0 (4)        | 0.0001|
| [15] I know how to get the non-medical help I/my family needs (e.g., educational, financial, social support). | 51.4 (18)                  | 11.4 (4)        | 37.1 (13)      | 73.1 (49)   | 10.5 (7)        | 16.4 (11)      | 0.047|
| [4a] When I think about the condition in my family, I get upset.   | 50.0 (17)                  | 20.6 (7)        | 29.5 (10)      | 52.2 (35)   | 22.4 (15)       | 25.4 (17)      | 0.92|
| [5a] I don’t know where to go to get the medical help I/my family needs.s(). | 48.6 (17)                  | 2.9 (1)         | 48.6 (17)      | 31.3 (21)   | 13.4 (9)        | 55.2 (37)      | 0.11|
| [22a] I am powerless to do anything about this condition in my family. | 42.9 (15)                  | 20.0 (7)        | 37.1 (13)      | 40.3 (27)   | 14.9 (10)       | 44.8 (30)      | 0.70|
| [10a] I don’t know what could be gained from each of the options available to me. | 36.4 (12)                  | 36.4 (12)       | 27.3 (9)       | 15.4 (10)   | 32.3 (21)       | 52.3 (34)      | 0.026|
| [21a] I feel guilty because I (might have) passed this condition on to my children. | 36.4 (12)                  | 45.5 (15)       | 18.2 (6)       | 34.3 (23)   | 17.9 (12)       | 47.8 (32)      | 0.003|
| [13a] In relation to the condition in my family, nothing I decide will change the future for my children/any children I might have. | 14.3 (5)                   | 40.0 (14)       | 45.7 (16)      | 24.2 (16)   | 21.2 (14)       | 54.6 (36)      | 0.12|
| [6] I can see that good things have come from having this condition in my family. | 11.4 (4)                   | 22.9 (8)        | 65.7 (23)      | 40.0 (26)   | 21.5 (14)       | 38.5 (25)      | 0.006|
| [7] I can control how this condition affects my family.            | 8.6 (3)                    | 14.3 (5)        | 77.1 (27)      | 25.8 (17)   | 18.2 (12)       | 56.1 (37)      | 0.07|

*a Fisher’s exact test, items with group differences at \( p \leq 0.05 \) are italicized. Due to missing data, total number of responses per item can vary

b Numbering of items in the survey

c Reverse coded for computing overall empowerment score
rare disease (24%, 8/33), followed by general (21.1%, 7/33), symptom focus (18.2%, 6/33), specific disease (6%, 2/33) and undiagnosed disease (6%, 2/33). Only two respondents, both parents, reported participating in support groups in the rare disease category. Parental participation is reflected in all six support group categories, while adult participation is reflected in four of the support group categories. It was not unusual for respondents to participate in more than one support group (100%, 4/4 adults; 33.3%, 4/12 parents) and more than one category of support group (75%, 3/4 adults; 33.3%, 4/12 parents). A higher percentage of adult participants were involved in “General Support” groups than parents (75 vs. 16.7%, respectively) and a higher percentage of parents, particularly mothers, were involved in the “special needs” groups than adult participants (50 vs. 0%, respectively). Only two respondents (12.5%) reported participation in groups designed for individuals impacted by undiagnosed conditions.

**Participant Comments**

Twenty-seven participants (26.5%), comprised of 11 adult participants (31.4%, 11/35) and 16 parents (23.9%, 16/67), provided comments at the end of the survey. Adult participants were not significantly more likely to provide responses than the parents (FE $p = 0.48$). Responses were categorized into five themes, with representation from adult participants and parents in all themes. Two themes involved the UDN itself: “Reasons for applying to the UDN” and “UDN program/process.” These comments generally reflected hope for the end of the diagnostic odyssey and appreciation for a program dedicated to individuals with undiagnosed conditions. Two themes captured emotional states brought on by living with an undiagnosed condition, such as feelings of uncertainty, and evidence of positive coping. These themes were labeled “challenges living undiagnosed” and “positive coping strategy.” A fifth theme, labeled “explaining survey responses,” reflected participants’ comments about why they did or did not respond to a survey item in a certain way. Table 4 provides illustrative comments for each category.

**Discussion**

The purpose of this study was to investigate UDN participant and parent empowerment prior to the UDN in-person evaluation in order to better understand baseline levels of empowerment in this population. Using the GCOS-24 measure (McAllister et al. 2011), we found that adults have significantly lower empowerment levels than parents of children with undiagnosed conditions. Although these groups differed in the proportion of participants affected with primarily neurological symptoms, there was no evidence that empowerment scores were explained by primary symptom category or other demographic variables, including respondent and child age and gender. Overall, these results are consistent with the findings of Spillmann et al. (2017) and provide further evidence that the experience of living with an undiagnosed condition differs between adult patients and parents of patients.

In our sample, the average GCOS-24 empowerment score was 112.67 (SD 18.33), with a parental average score of 116.5 (SD 18.1) and an adult average score of 105.4 (SD 16.94). In a study of 61 individuals with suspected genetic conditions (cancer, intellectual disability/cytogenetics, eye disorders, other) referred for a genetics consultation in Denmark, the average GCOS-24 empowerment score was 120.8 (SD 15.1) prior to consultation (Diness et al. 2017). In a study of individuals referred to one of five clinical genetics services in the UK (sample sizes ranging from 42 to 74), the average GCOS-24 empowerment scores ranged from 104 to 121 (SD 8.9–25.8) across the five centers (McAllister 2016). Finally, in a sample of 45 adults in Canada with a personal history of psychiatric illness for which the etiology is unknown, the average GCOS-24 score prior to genetic counseling was 109.29 (SD 14.7) (Inglis et al. 2015). Of note, we found that empowerment levels of the adults with a psychiatric illness are similar to levels of UDN adult participants and significantly lower than those of UDN parents, further bolstering the evidence that the experience of living with an undiagnosed condition differs between adult patients and parents. In light of our finding of the importance of distinguishing between adult patients and parents of a child, we did not compare GCOS-24 scores with the other two previous studies (Diness et al. 2017; McAllister 2016) because insufficient information about those patient samples limited our ability to interpret the results. However, overall, it does appear that the empowerment levels of our overall UDN cohort fall within the range reported in studies of patients/families with a variety of conditions referred for genetic evaluation or genetic counseling.

Responses to specific items on the empowerment measure revealed that nearly all participants and parents understood why they were referred to the UDN for evaluation. In addition, the majority of respondents felt that they could explain what the condition meant to their family and others, could cope with having the condition in the family, felt positive about the future, could make plans and decisions, and understand the impact of the condition on (future) children. The ability to cope, make plans, and feel positive about the future in our sample are consistent with a recent report of the psychosocial profile of parents of a child with an undiagnosed condition at the Duke UDN Clinical Site in which parents were found to have high coping self-efficacy, engagement in their child’s healthcare, and tolerance for uncertainty (McConkie-Rosell et al. 2018). Additional research in adults with an undiagnosed condition is needed to ascertain if they have a similar psychosocial profile.
More than half of our respondents also felt that the condition was upsetting and that they experience uncertainty about other family members having the condition. This finding is consistent with the suffering, frustration, and uncertainty described in the narratives of patients applying to the UDN (Spillmann et al. 2017) and the finding that more than a third of parents of a child with an undiagnosed condition participating at the Duke UDN Clinical Site meet criteria for mild to moderate depression or anxiety (McConkie-Rosell et al. 2018). The partial overlap of participants across these studies offers a more comprehensive picture of the challenges associated with undiagnosed conditions, particularly for parents. These results suggest possible sites of intervention to address these concerns.

Item responses also revealed differences between adult participants and parents. Not only were the majority of parents more hopeful for their child’s future compared to adult participants, parents were also significantly more likely to report knowing how to get nonmedical help and what can be gained from available options. These findings suggest several possibilities, including that more support may be available for parents of children with medical issues, that parents are more able to access support than adult participants because the adults do not feel well, or, extrapolating from the work of Spillmann et al. (2017), that adults with undiagnosed conditions are concerned about having to continue validating their illness if they try to reach out for additional help. Parents were also significantly more likely to report seeing good things come from

---

### Table 3 Support group participation

| Type of support       | Specific examples                                                                 | Respondents               |
|-----------------------|-----------------------------------------------------------------------------------|---------------------------|
| General               | The Cause (church)                                                                | [Participant 89—adult]    |
|                       | Telephone support groups                                                          | [Participant 45—adult]    |
|                       | Local support group                                                               | [Participant 45—adult]    |
|                       | Online forums                                                                     | [Participant 92—adult]    |
|                       | Community support                                                                 | [Participant 92—adult]    |
|                       | Parent support group                                                              | [Participant 46—mom]     |
|                       | Individual and marriage counseling                                                | [Participant 83—mom]     |
| Special needs         | Facebook groups                                                                   | [Participant 62—mom]     |
|                       | Friends of children with complex conditions                                       | [Participant 10—mom]    |
|                       | Educators and therapists at school for complex children                            | [Participant 10—mom]    |
|                       | Special Education Parents Advisory Council                                        | [Participant 22—mom]    |
|                       | Local Special Olympics chapter                                                     | [Participant 22—mom]    |
|                       | Online support group                                                              | [Participant 66—mom]    |
|                       | Jewish mothers of children with special needs                                      | [Participant 104—mom]  |
|                       | Physician Mothers of Children with Special Needs                                   | [Participant 18—mom]    |
| Symptom focus         | Friends of Brain Injury                                                            | [Participant 89—adult]    |
|                       | Spinal cord disease online support group                                          | [Participant 45—adult]    |
|                       | Auto-inflammatory Alliance Facebook page                                          | [Participant 121—mom]  |
|                       | Online pediatric epilepsy support groups                                          | [Participant 22—mom]    |
|                       | Infantile spasms group                                                            | [Participant 18—mom]    |
|                       | Facebook group-hypotonia parents connection                                       | [Participant 96—dad]   |
| Specific disease       | National Urea Cycle Disorders Foundation                                          | [Participant 10—mom]    |
|                       | Marinesco-Sjogren Syndrome Support Group                                          | [Participant 64—dad]    |
| Rare disease           | Utah Rare                                                                         | [Participant 49—adult]    |
|                       | Wisconsin Rare                                                                    | [Participant 83—mom]    |
|                       | RunmyDNA.com                                                                      |                          |
|                       | NORD                                                                              |                          |
|                       | Every Life Foundation for Rare Diseases                                           |                          |
|                       | Rare Disease Legislative Advocates                                                 |                          |
|                       | Global Genes                                                                       |                          |
|                       | Rare disease community for connection and support                                  |                          |
| Undiagnosed disease   | Rare and Undiagnosed Disease Network                                             | [Participant 49—adult]    |
|                       | San Diego Undiagnosed Family Support Group                                        | [Participant 87—dad]    |
Table 4  Themes from open-ended survey responses

| Theme for applying to the UDN | Adult participants | Parents |
|-------------------------------|--------------------|---------|
| “...hope that even if I don’t find answers for my own condition, that I might be able to help someone else.” [participant 3—adult] | “As a mother my reasoning for wanting [my son] to be part of the study is to get some answers as to the why his medical problems developed. I understand that a “cure” is not the objective. If his medical problems can be given a name, a link, and a possible understanding of the progression and what could potentially go wrong would be vital information not just for [my son] but his sister and [his] future potential children. I as a mother just want [my son] to live a long happy life.” [participant 16—mom] |
| “For me an unsolved problem is an exciting opportunities for scientific advancement.” [participant 24—adult] | “I hope one day he has a diagnosis. I hope one day we can help him so that we aren’t afraid of what happens when he gets sick. I hope that one day when someone asks me what happened to him, I can better explain why he is different…” [participant 61—mom] |
| “This testing for me is my last go to try to figure out what I really have. I’ve been disappointed before with testing and this is just another opportunity to find out more or nothing at all. I just want to know why I’m the only one who has this problem and if I have a child will they get the bad gene that I have.” [participant 44—adult] | “It creates a lot of anxiety because my daughter can’t communicate with me or the doctors. I feel responsible for [my daughter’s] outcomes because it seems like I’m always the one who knows when there is a problem… It is stressful to make plans because one never knows when something is going to go wrong, this has been worse since [my daughter] was diagnosed with epilepsy, then a tumor and then infection. I asked the doctor to put in the letter for [my daughter] because it just seemed like there was something more going on with her but no doctor is looking at the whole picture.” [participant 4—mom] |
| “It is about 2 weeks before my clinic visit and I must say that everyone has been amazing and so helpful. I could not ask for a better experience thus far. I am thankful and so grateful for this opportunity…” [participant 3—adult] | “The hardest thing for me is not knowing what lies ahead. I continually exceed all of my expectations! But, what happened? Why did he get sick? What if he gets sick again? How do I help him? Not having answers to these questions, makes me feel powerless.” [participant 61—mom] |
| “I just wanted to thank all of the people who are in charge of this research study, your [sic] going to change a lot of lives for the better and this could be the one thing that could change my life if something comes out of the study.” [participant 44—adult] | “I am worried that there could be no cure or treatment for my daughter’s medical condition, and that that will affect her learning, her normal life and on adulthood her independent living. I would like my daughter to one day be able to go to college and have a normal life. Worried of what would happen to her when us, as parents, no longer exist, if she makes no progress.” [participant 110—dad] |
| “We say that we live in a diagnostic odyssey times four. Being the mother of three children that suffer with an undiagnosed rare disease while being undiagnosed as well, is very difficult.” [participant 49—adult] | “As I have explained to [my son] throughout his young life some people have to do maintenance on their body more so than others to keep it running well, like a car. We cannot control if things go wrong, but we can do our best to try to prevent further problems. If that involves continuous doctor appointments, medications, procedures and surgeries than that is what we must do. It will not interfere with having a happy fulfilling life. As the study goes, [my son] understands knowledge is power, and whatever we can learn about his medical conditions can only give us power in making the best decisions possible for his medical care and future. Thank you” [participant 16—mom] |
| “Our family is our support group, because no one else has this condition and no one else can even relate to this experience we have been through” [participant 111—adult] | “We are very fortunate to have met so many people that have advocated and continue to support [our daughter] and our family. We have many therapists and medical professionals and teachers that have witnessed [our daughter’s] episodes and |
| UDN program/ process | “As a mother I am very thankful for UDN.” [participant 21—mom] | |
having the condition in the family and feeling a sense of control over how the condition affects the family, aspects that may be associated with better coping and adaptation (Madeo et al. 2012). Overall, these differences suggest that, compared to adult participants’ levels of empowerment related to the potential genetic aspects and chronic issues of their own condition, parents enter the UDN process with increased levels of empowerment related to these aspects of their child’s condition across a variety of the domains, including hope, emotional regulation, and cognitive and behavioral control.

In our sample, 15.7% (16/102) of respondents reported support group involvement, with adult participants and parents (primarily mothers) equally likely to be involved. This rate is lower than the 53.5% (299/620) of adults with a rare disease diagnosis in Australia who reported using a support group in the last 12 months (Molster et al. 2016), and suggests that lack of a diagnosis may hinder support group participation. Also of note, in our sample, there was no evidence of an association between support group participation across a variety of the domains, including hope, emotional regulation, and cognitive and behavioral control.

The goals of support groups include helping people cope with their disease, facilitating social interactions and networking, and encouraging group advocacy (Finlayson and Cho 2011). At their essence, support groups provide an avenue for personal contact with other individuals who have gone through a similar experience. One possible explanation for the lack of association between support group participation and empowerment in our UDN sample is that groups available to patients and families with undiagnosed conditions cannot meet the need for a shared experience. A study of the impact of online support groups on empowerment processes and outcomes in individuals with chronic disease found that the most common empowerment process was associating and finding similarities with another support group member (Bartlett and Coulson 2011). The ability to find commonalities with other members was associated with a number of empowerment outcomes, including feeling better informed, more confident in the physician and treatment, more acceptance of illness, and more optimism and hope for the future. By virtue of being affected with an undiagnosed condition, patients and families may have difficulty identifying support groups that offer a similar shared experience. The ability to find commonalities often ends with the sharing of the search for a diagnosis and the experience of frustration of the diagnostic odyssey. As a result, empowerment processes may be inhibited. In our study, one respondent specifically commented on the challenge of finding a support group relevant to the needs of someone with an undiagnosed condition—a challenge that has been previously noted (Lewis et al. 2010).

Regardless of the challenges, for some UDN participants and family members, the desire to find individuals with similar experiences is strong, evident by reported support group involvement. These support groups fell into six categories: “general,” “special needs,” “symptom focus,” “specific disease,” “rare disease,” and “undiagnosed disease.” The categories with the greatest participation included “special needs” and “rare disease,” although only two participants listed participation in the “rare disease” category. While more adults participated in “general” support groups than parents and more parents participated in “special needs” support groups than adults, overall adult and parental participation
was reflected in all or most of the support group categories. These results suggest that no single support group or support group category completely addresses the needs of individuals and families impacted by undiagnosed conditions. In fact, among the categories of support groups identified by our UDN participants and parents, support groups for undiagnosed conditions were the least frequently cited, suggesting a need for groups for individuals impacted by undiagnosed conditions. In order to address this and other needs of those affected by undiagnosed conditions, the UDN recently created a group of participants, called the Participant Engagement and Empowerment Resource (PEER). Future research is needed to evaluate the impact of PEER on empowerment levels of adult patients and parents participating in the UDN.

Assessment of open-ended comments at the end of the survey provided additional insight into our cohort. Comments in the two UDN-related themes generally reflected hope for the end of the diagnostic odyssey and appreciation for a program dedicated to individuals with undiagnosed conditions. Because investigation of rare and undiagnosed conditions requires multidisciplinary teams involving clinicians, genetic counselors, and basic researchers, the UDN-related themes highlight the importance, from the patient point of view, of developing programs and strategies that bridge the clinical research gap to advance patient care. Two other themes captured emotional states brought on by living with an undiagnosed condition, like feelings of uncertainty, and evidence of positive coping. Findings of hope and positive coping were also observed in the set of narratives written by UDN applicants or parents on behalf of a child (Spillmann et al. 2017) and as part of a psychosocial profile of parents of a child with an undiagnosed disorder (McConkie-Rosell et al. 2018).

Limitations

Patient empowerment provides one useful strategy for conceptualizing and measuring outcomes of evaluation in an undiagnosed disease clinic setting. However, in the open-ended survey responses, some participants noted that it was challenging to respond to GCOS-24 items related to children for individuals without children and items related to “condition” for those of whom “condition” implies “diagnosis.” Furthermore, the GCOS-24 operationalization of patient empowerment may not fully capture all of the important aspects of living with an undiagnosed condition, or all of the outcomes from evaluation in an undiagnosed disease clinic setting. Future research could address if there are better measures of patient empowerment for this population. We, however, found that the GCOS-24 measure had excellent internal consistency, high completion rates, and scores that fall within a range of three other studies using this measure in populations that included individuals with potential genetic conditions, suggesting that the GCOS-24 performs reasonably well in a population impacted by undiagnosed conditions.

This study sample is composed of adults and parents who applied to the UDN, which takes time and effort. As a result, our findings may not generalize to all individuals and families impacted by undiagnosed conditions. In addition, because our participants completed the survey after consent involving considerable interaction with UDN staff, usually a genetic counselor, it is possible that their baseline empowerment scores are higher than if they had completed the survey prior to any interaction with the UDN team. As a result, effect sizes for changes in empowerment later in the UDN process may be weakened. We also did not correct for multiple testing when we examined each of the GCOS-24 items for participant group differences because it is difficult to know how best to do this when the items of a scale are not independent. Additional research with larger samples can provide further insight into the robustness of these group differences. Finally, the sample is composed primarily of Caucasian individuals, and so generalizability to other groups should be done with caution.

Implications for Genetic Counseling

Our results indicate that adult patients and parents have different experiences living with undiagnosed conditions. This understanding can be applied when establishing rapport and identifying needs as part of genetic counseling practice, whether counseling patients with undiagnosed conditions within a regular clinical genetics service or within an undiagnosed disease clinic setting. This work also revealed that a small percentage of patients and parents affected by undiagnosed conditions participate in support groups and that, for the most part, these support groups do not specifically serve the undiagnosed. As genetic counseling involves providing resources for patients, genetic counselors can consider taking a proactive role in developing support groups or other methods for supporting patients and families affected by undiagnosed conditions.

Future Research

Given the evidence of increased empowerment several weeks after genetic counseling and evaluation (Inglis et al. 2015; McAllister et al. 2011), we hypothesize that adult patients and parents will experience increased empowerment following the UDN in-person evaluation, which will need to be assessed. Future research on support group participation is also warranted. Given the small number of individuals reporting participation in support groups in this study, replication of this finding in a larger sample is essential. We did not
ascertain whether or not participants wanted to be part of a support group. However, parents of a child with a rare disease have been repeatedly shown to identify access to a support group as an important means of support (Pelentsov et al. 2015). Hence, research is also needed to explore reasons why participants and parents of children with undiagnosed conditions participate or not in a support group. Since support group participation has been shown to increase levels of empowerment in other studies, examining the role of support groups or other resources specific to patients and families affected by undiagnosed conditions would be beneficial. In addition, the impact of different resources and strategies on adult patient and parent levels of empowerment should be measured.

**Conclusion**

This study demonstrated that, prior to the UDN in-person evaluation, parents of children with undiagnosed conditions have higher levels of empowerment related to potential genetic and chronic aspects of a condition than adult participants. Our findings suggest a need for support group resources specifically designed for patients and families impacted by undiagnosed conditions, tailored differently for adult patients and parents. Future research is needed to determine if there are specific factors that influence empowerment during UDN participation, and if these factors are identified, developing targeted approaches in the UDN protocol to increase empowerment. Ideally, this work will provide a foundation for improving levels of empowerment, determining the extent to which patient/family empowerment influences downstream outcomes, and developing protocols for enhancing patient empowerment in clinics devoted to individuals with undiagnosed conditions nationally and worldwide.

**Acknowledgements** We thank the individuals and families participating in the Undiagnosed Diseases Network. This work is dedicated to the memory of Kimberly Strong. Professor Bonnie Leroy served as editor on the manuscript review process and publication decision.

**Author Contributions** CGSP contributed to the study design, data collection, data analysis, and results interpretation and wrote the first draft of the manuscript. AM contributed to the study design, data collection, data analysis, results interpretation, and manuscript revisions. IH and KL contributed to the study design, results interpretation, and manuscript revisions. JSS contributed to the study design, data analysis, results interpretation, and manuscript revisions. LCB, ND, MH, SL, KS, and RCS contributed to the study design, data collection, results interpretation, and manuscript revisions. EB contributed to results interpretation and manuscript revisions.

**Funding Information** Research reported in this manuscript was supported by the NIH Common Fund, through the Office of Strategic Coordination/Office of the NIH Director under Award Numbers U01HG007073, U01HG007672, U01HG007690, U01HG007674, and U01HG007530. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

**Compliance with Ethical Standards**

**Conflict of Interest** Christina G.S. Palmer, Allyn McConkie-Rosell, Ingrid Holm, Kimberly LeBlanc, Janet S. Sinsheimer, Lauren C. Briere, Naghmeh Dorrani, Matthew Herzog, Sharyn Lincoln, Kelly Schoch, Rebecca C. Spillmann, and Elly Brokamp declare that they have no conflict of interest.

**Human Studies and Informed Consent** All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation and with the Helsinki Declaration of 1975, as revised in 2000. Informed consent was obtained from all participants for being included in this study.

**Animal Studies** No animal studies were carried out by the authors for this article.

**Consortia**

Members of the Undiagnosed Diseases Network are David R. Adams, Mercedes E. Alejandro, Patrick Allard, Euan A. Ashley, Mahshid S. Azamian, Carlos A. Bacino, Ashok Balasubramanyam, Hayk Barseghyan, Gabriel F. Batzli, Alan H. Beggs, Hugo J. Bellen, Jonathan A. Bernstein, Anna Bican, David P. Bick, Camille L. Birch, Devon Bonner, Braden E. Boone, Bret L. Bostwick, Lauren C. Briere, Donna M. Brown, Matthew Brush, Elizabeth A. Burke, Lindsay C. Burrage, Shan Chen, Gary D. Clark, Terra R. Coakley, Joy D. Cogan, Cynthia M. Cooper, Heidi Cope, William J. Craig, Precilla D’Souza, Mariska Davids, Jean M. Davidson, Jyoti G. Dayal, Esteban C. Dell’Angelica, Shweta U. Dhar, Ani Dillon, Katrina M. Dipple, Laurel A. Donnell-Fink, Naghmeh Dorrani, Daniel C. Dorset, Emilie D. Douine, David D. Draper, Annika M. Dries, David J. Eckstein, Lisa T. Emrick, Christine M. Eng, Gregory M. Enns, Ascia Eskin, Cecilia Esteses, Tyra Estwick, Liliana Fernandez, Paul G. Fisher, Brent L. Fogel, Noah D. Friedman, William A. Gahl, Emily Glanton, Rena A. Godfrey, David B. Goldstein, Sarah E. Gould, Jean-Philippe F. Gouridine, Catherine A. Groden, Andrea L. Gropman, Melissa Haendel, Rizwan Hamid, Neil A. Hanchard, Lori H. Handley, Matthew R. Herzog, Ingrid A. Holm, Jason Hom, Ellen M. Howerton, Yong Huang, Howard J. Jacob, Mahim Jain, Yong-hui Jiang, Jean M. Johnston, Angela L. Jones, David M. Koehler, Isaac S. Kohane, Jennifer N. Kohler, Donna M. Krasnewich, Elizabeth L. Krieg, Joel B. Krier, Jennifer E. Kyle, Seema R. Lalani, C. Christopher Lau, Jozef Lazar, Brenda H. Lee, Hane Lee, Shawn E. Levy, Richard A. Lewis, Sharyn A. Lincoln, Allen Lipson, Sandra K. Loo, Joseph Loscalzo, Richard L. Maas, Ellen F. Macnamara, Calum A. MacRae, Valerie V. Maduro, Marta M. Majcherska, May Christine V. Malicdan, Laura A.
Mamounas, Teri A. Manolio, Thomas C. Markello, Ronit Marom, Julian A. Martínez-Agosto, Shruiti Marwaha, Thomas May, Allyn McConkie-Rosell, Colleen E. McCormack, Alexa T. McCray, Jason D. Merker, Thomas O. Metz, Matthew Might, Paolo M. Moretti, John J. Mulvihill, Jennifer L. Murphy, Donna M. Munzy, Michele E. Nehrebecky, Stan F. Nelson, J. Scott Newberry, John H. Newman, Sarah K. Nicholas, Donna Novacic, Jordan S. Orange, J. Carl Pallais, Christina GS. Palmer, Jeanette C. Papp, Neil H. Parker, Loren DM. Pena, John A. Phillips III, Jennifer E. Posey, John H. Postlethwait, Lorraine Potocki, Barbara N. Pusey, Chloé M. Reuter, Amy K. Robertson, Lance H. Rodan, Jill A. Rosenfeld, Jacinda B. Sampson, Susan L. Samson, Kelly Schoch, Molly C. Schroeder, Daryl A. Scott, Prashanth Sharma, Vandana Shashi, Edwin K. Silverman, Janet S. Sinhseimer, Kevin S. Smith, Ariane G. Soldatos, Rebecca C. Spillmann, Kimberly Splinter, Joan M. Stoler, Nicholas Stong, Jennifer A. Sullivan, David A. Sweetser, Cynthia J. Tiftt, Camilo Toro, Alyssa A. Tran, Tiina K. Urv, Zaheer M. Valivullah, Eric Vilain, Tiphanie P. Vogel, Daryl M. Waggott, Colleen E. Wahl, Nicole M. Walley, Chris A. Walsh, Michael F. Wangler, Patricia A. Ward, Katrina M. Waters, Bobbie-Jo M. Webb-Robertson, Monte Westerfield, Matthew T. Wheeler, Anastasia L. Wise, Lynne A. Wolfe, Elizabeth A. Worthey, Shinya Yamamoto, Yaping Yang, Guoyan Yu, Diane B. Zastrow, Chunli Zhao, Allison Zheng

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

Bartlett, Y. K., & Coulson, N. S. (2011). An investigation into the empowerment effects of using online support groups and how this affects health professional/patient communication. Patient Education and Counseling, 83(1), 113–119. https://doi.org/10.1016/j.pec.2010.05.029.

Bolen, S. D., Chandar, A., Falk-Ytter, C., Tyler, C., Perzynski, A. T., Gertz, A. M., et al. (2014). Effectiveness and safety of patient activation interventions for adults with type 2 diabetes: systematic review, meta-analysis, and meta-regression. Journal of General Internal Medicine, 29(8), 1166–1176.

Chen, M. F., Tsai, C.-T., Hsu, S. M., Tu, S. Y., Kao, P. L., & Chen, S.-L. (2013). Patient perceptions of empowerment processes, health outcomes and related factors in patients living with diabetes in Taiwan: a cross-sectional survey. Journal of Community Health Nursing, 30(4), 201–215.

Chong, J. X., Buckingham, K. J., Jiangiani, S. N., Boehm, C., Sobreira, N., Smith, J. D., et al. (2015). The genetic basis of Mendelian phenotypes: discoveries, challenges, and opportunities. American Journal of Human Genetics, 97, 199–215.

Diness, B. R., Overbeck, G., Hjortshøj, T. D., Hammer, T. B., Timsøel, S., Sorensen, E., & McAllister, M. (2017). Translation and adaptation of the Genetic Counseling Outcome Scale (GCOS024) for use in Denmark. Journal of Genetic Counseling. https://doi.org/10.1007/s10897-017-0086-7.

EURODIS. (2018). What is a rare disease? Retrieved from http://www.eurodis.org/sites/default/files/publications/Fact_Sheet_RD.pdf Accessed 03 Jan 2018.

Finlayson, M. L., & Cho, C. C. (2011). A profile of support group use and need among middle-aged and older adults with multiple sclerosis. Journal Gerontological Social Work, 54(5), 475–493.

Gahl, W. A., Wise, A. L., & Ashley, E. A. (2015). The undiagnosed diseases network of the National Institutes of Health: a national extension. JAMA, 314(17), 1797–1798.

Hsieh, H. F., & Shannon, S. E. (2005). Three approaches to qualitative content analysis. Qualitative Research Health, 15, 1277–1288.

Inglis, A., Koehn, D., McGillivray, B., Stewart, S. E., & Austin, J. (2015). Evaluating a unique, specialist psychiatric genetic counseling clinic: uptake and impact. Clinical Genetics, 87, 218–224.

Lewis, C., Skorton, H., & Jones, R. (2010). Living without a diagnosis: the parental experience. Genetic Testing and Molecular Biomarkers, 14(6), 807–815.

Madeo, A. C., O’Brien, K. E., Bernhardt, B. A., & Biesecker, B. B. (2012). Factors associated with perceived uncertainty among parents of children with undiagnosed medical conditions. American Journal of Medical Genetics Part A, 158A(4), 1877–1884.

McAllister, M. (2016). Genomics and patient empowerment. In D. K. R. Chadwick (Ed.), Genomics and society (pp. 39–68). Philadelphia: Elsevier.

McAllister, M., Payne, K., MacLeod, R., Nicholls, S., Donnai, D., & Davies, L. (2008). Patient empowerment in clinical genetics services. Journal of Health Psychology, 13, 895–905.

McAllister, M., Wood, A. M., Dunn, G., Shiloh, S., & Todd, C. (2011). The genetic counseling outcome scale: a new patient-reported outcome measure for clinical genetics services. Clinical Genetics, 79, 413–424.

McConkie-Rosell, A., & Sullivan, J. (1999). Genetic counseling—stress, coping, and the empowerment perspective. Journal of Genetic Counseling, 8, 345–358.

McConkie-Rosell, A., Hooper, S. R., Pena, L. D. M., Schoch, K., Spillmann, R. C., Jiang, Y.-H., … Shashi, V. (2018). Psychosocial profiles of parents of children with undiagnosed diseases: managing well or just managing? Journal of Genetic Counseling.

Molster, C., Urwin, D., De Pietro, L., Fookes, M., Petrie, D., van der Laan, S., & Dawkins, H. (2016). Survey of healthcare experiences of Australian adults living with rare diseases. Orphanet Journal of Rare Diseases, 11.

National Institutes of Health. (2017). FAQs about rare diseases. Retrieved from https://rarediseases.info.nih.gov/diseases/pages/31/faqs-about-rare-diseases date last updated 11/30/2017, date accessed 03 Jan 2018.

Pelentsov, L. J., Laws, T. A., & Esterman, A. J. (2015). The supportive care needs of parents caring for a child with a rare disease: a scoping review. Disability and Health Journal, 8(4), 475–491.

Ramoni, R. B., Mulvihill, J. J., Adams, D. R., Allard, P., Ashley, E. A., Bernstein, J. A., et al. (2017). The Undiagnosed Diseases Network: accelerating discovery about health and disease. American Journal of Human Genetics, 100(2), 185–192.

Satu, E., Kaarialainen, M., Ouitti, K., Polkki, T., Utriainen, K., & Kyngas, H. (2014). Qualitative content analysis: a focus on trustworthiness. SAGE Open, 4, 1–10.

Schmidt, M., Eckardt, R., Scholtz, K., Neuner, B., von Dossow-Hanfstingl, V., Sehoulí, J., … PERATECS Group. (2015). Patient empowerment improved perioperative quality of care in cancer patients aged >=65 years—a randomized controlled trial. PLoS One, 10(9).
Spillmann, R. C., McConkie-Rosell, A., Pena, L., Jiang, Y.-H., Undiagnosed Diseases Network, Schoch, K., et al. (2017). A window into living with an undiagnosed disease: illness narratives from the Undiagnosed Diseases Network. *Orphanet Journal of Rare Diseases, 12*(71).

Wallerstein, N. (2006). *What is the evidence on effectiveness of empowerment to improve health?*. Retrieved from Copenhagen: http://www.euro.who.int/en/data-and-evidence/evidence-informed-policy-making/publications/pre2009/what-is-the-evidence-on-effectiveness-of-empowerment-to-improve-health.

Yanes, T., Humphreys, L., McInerney-Leo, A., & Biesecker, B. (2017). Factors associated with parental adaptation to children with an undiagnosed medical condition. *Journal of Genetic Counseling, 26*, 829–840.

Zurynski, Y., Deverell, M., Dalkeith, T., Johnson, S., Christodoulou, J., Leonard, H., … APSU Rare Diseases Impacts on Families Study group. (2017). Australian children living with rare diseases: experiences of diagnosis and perceived consequences of diagnostic delays. *Orphanet Journal of Rare Diseases, 12*.